AVEO Pharmaceuticals, Inc. (AVEO) Receives Average Recommendation of “Hold” from Brokerages

Shares of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) have been given a consensus recommendation of “Hold” by the eight analysts that are currently covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating on the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $4.38.

A number of brokerages have recently issued reports on AVEO. Zacks Investment Research upgraded shares of AVEO Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, January 9th. B. Riley started coverage on shares of AVEO Pharmaceuticals in a report on Monday, November 13th. They issued a “buy” rating and a $5.00 target price for the company. BidaskClub downgraded shares of AVEO Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Tuesday, January 9th. started coverage on shares of AVEO Pharmaceuticals in a report on Wednesday, November 15th. They issued a “buy” rating and a $5.00 target price for the company. Finally, Seaport Global Securities reiterated a “buy” rating on shares of AVEO Pharmaceuticals in a report on Friday, October 6th.

Shares of AVEO Pharmaceuticals (AVEO) opened at $3.10 on Friday. The stock has a market cap of $366.75, a P/E ratio of -4.37 and a beta of 1.14. The company has a current ratio of 2.33, a quick ratio of 2.33 and a debt-to-equity ratio of -0.32. AVEO Pharmaceuticals has a 1-year low of $0.50 and a 1-year high of $4.24.

A number of institutional investors have recently bought and sold shares of AVEO. Fore Research & Management LP acquired a new stake in AVEO Pharmaceuticals in the 2nd quarter valued at approximately $111,000. Victory Capital Management Inc. acquired a new stake in AVEO Pharmaceuticals in the 3rd quarter valued at approximately $164,000. Rehmann Capital Advisory Group acquired a new stake in AVEO Pharmaceuticals in the 3rd quarter valued at approximately $193,000. OxFORD Asset Management LLP acquired a new stake in AVEO Pharmaceuticals in the 3rd quarter valued at approximately $228,000. Finally, Essex Investment Management Co. LLC acquired a new position in shares of AVEO Pharmaceuticals in the third quarter worth $550,000. Hedge funds and other institutional investors own 50.91% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This story was reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this story can be viewed at https://www.americanbankingnews.com/2018/01/14/aveo-pharmaceuticals-inc-aveo-receives-average-recommendation-of-hold-from-brokerages.html.

AVEO Pharmaceuticals Company Profile

AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.

Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply